Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P1066 | DOI: 10.1530/endoabs.56.P1066

1Çorum Erol Olçok Education and Research Hospital, Department of Endocrinology and Metabolism, Çorum, Turkey; 2Ankara Numune Education and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey.

Glucagon-like peptide-1 (GLP-1) is an increatin hormon with various glucoregulatory effects, and exenatide is a GLP-1 receptor agonist used in the management of type 2 diabetes mellitus. C cell hypertrophy was seen in animals treated with GLP-1 receptor agonists, but the effects of GLP-1 agonists on C-cell proliferation or neoplasia in humans have not been documented formerly. The aim of this study was to evaluate the impact of exenatide on structural and functional features of the thyroid in patients with T2DM treated with exenatide. Fourty-eight patients with T2DM were included in the study. 5 μg exenatide was started to all patients twice daily.After 4 weeks the dose was increased to 10 μg twice daily.Four patients who had severe vomiting were excluded. Serum free triiodothyronine (T3), free thyroxine (T4), thyrotropin (TSH), anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-Tg), carcino-embryonic antigen (CEA) and calcitonin were measured and thyroid ultrasonography was performed before the treatment was started and after 6th month. Fourty-one women and three men were included in the analysis with a mean age of 47.84±7.37 years. The laboratory parameters and thyroid ultrasonographic features are summarized in the table. A significantly statistically decrease was achieved in TSH (P<0.001) and thyroid volume (P:0.047). The statistical analysis was performed with 32 patients who were not using levothyroxine at the beginning, and TSH decrease was still statistically significant (P:0.022), whereas the reduction of the thyroid volume lost its significant difference (P:0.130). In conclusion, our study showed no difference in serum CEA and calcitonin level after 6 months of exenatide therapy, whereas a reduction in the thyroid volume was achieved for the first time in the literature.

Table 1 Demographic features and laboratory parameters at the beginning and after 6 months
Before exenatide6 months after exenatideP
Free T40.88±0.130.89±0.090.888
Free T33.38±0.453.50±0.320.150
Anti TPO64.88±158.3357.36±141.790.072
Anti TG11.57±39.0510.85±37.370.120
Thyroid volume16.42±15.5914.95±13.280.047

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts